Potential prostate cancer patients benefit from osteoporosis drug.

Recent study: More than 100 prostate cancer patients treated with androgen deprivation therapy, which lowers testosterone levels and often causes bone loss, took either the osteoporosis drug alendronate (Fosamax) or a placebo for one year.

Result: Bone mass in the spine increased by 3.7% in those taking alendronate compared with a decline in the placebo group.

Want to Keep Reading?

Continue reading with a Health Confidential membership.

Sign up now Already have an account? Sign in